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Abstract 
 1,2,3-triazole-based heterocycles have previously been shown to possess significant 
anticancer activity in various tumor models. In the present study, we attached a 1,2,3-triazole 
moiety to the third position of a 1,2-benzisoxazole heterocycle via Copper (I)-catalyzed 
azide-alkyne cycloaddition (CuAAC) with various alkynes and established for the title 
compounds significant antiproliferative effect against human acute myeloid leukemia (AML) 
cells. Among the tested compounds, 3-(4-(4-phenoxyphenyl)-1H-1,2,3-triazol-1-
yl)benzo[d]isoxazole (PTB) was found to be the most potent antiproliferative agent with an 
IC50 of 2 µM against MV4-11 cells using MTT assay. Notably, PTB induced cytotoxicity in 
MOLM13, MOLM14 and MV4-11 cells with selectivity over normal bone marrow cells 
(C57BL/6). Furthermore, PTB was found to induce cytotoxicity by increasing apoptosis of 
AML cells (MOLM13, MOLM14 and MV4-11) as well as sub-G1 cell population and 
apoptotic cells at submicromolar concentrations, as shown by flow cytometry and Annexin-V 
staining, respectively. On the protein level we suggested histone deacetylases (HDACs) as 
the potential protein target of those compounds in silico, and the predicted target was next 
experimentally validated by measuring the variations in the levels of p21, cyclin D and 
acetylation of histone H3 and tubulin. Molecular docking analysis of the title compounds 
with the second deacetylase domain of HDAC6 displayed high degree of shape 
complementarity to the binding site of the enzyme, forming multiple molecular interactions 
in the hydrophobic region as well as a hydrogen bond to the phenol side-chain of Tyr-782. 
Thus, 1,2,3-triazole derivatives appear to represent a class of novel, biologically active 
ligands against histone deacetylases which deserve to be further evaluated in their 
applications in the cancer field. 
Keywords: Histone Deacetylase; 1,2,3-Triazoles; Histone 3 Acetylation; Acute Myeloid 
Leukemia. 
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1. Introduction 
Transformation of normal cell to cancerous can be due to deregulation in 
proliferation, differentiation, apoptosis and epigenetic modifications.
1
 The significance of 
epigenetics in progression of various cancers especially in relevance to the role of histone 
deacetylase (HDAC) in oncogenesis has been well-demonstrated 
2, 3
 and implementation of 
histone deacetylase inhibitors (HDI) is of great appreciation since the discovery of sodium 
butyrate.
4-6
 Histone deacetylases are chromatin remodelling enzymes able to deacetylate 
lysine residues present on histones, with the effect of regulating gene transcription.
7
 The 
effect of this acetylation or deacetylation is rather profound - in cancer cells it has been found 
that HDAC inhibition modulates the transcriptional activity of about 1-2 % genes.
8
 Extensive 
research on the discovery of HDIs resulted in the development of several small molecules as 
anticancer agents.
9, 10
 Varinostat and romidepsin are the FDA approved HDIs approved for 
the treatment of cutaneous T cell lymphoma and currently many more HDIs are in clinical 
trials.
11, 12
 Many of these HDIs are reported to induce their anticancer effect by modulating 
both the acetylation of histones via their primary effects on HDACs, but many of them have 
also been found to modulate non-histone proteins, including tubulin.
13
  
Triazole derivatives have been proved to possess various pharmacological properties 
including antiproliferative, antiretroviral, antimicrobial, anticonvulsant and transforming 
growth factor β1 type 1 receptor inhibition.14-19 In addition, 3-substitued-1,2-benzisoxazoles 
have been used as prodrugs in medicinal chemistry, in which 1,2-benzisoxazole 
phosphorodiamidates are known to act as prodrugs of phosphoramide mustard that require 
bioreductive activation.
20, 21
 Also, benzisoxazole was evaluated for their ability to function as 
substrates for recombinant human NAD(P)H:quinone oxidoreductase that upregulated in 
cancer cells.
22
 In continuation of our effort to synthesize various bioactive heterocycles 
including 3-substituted-1,2-benzisoxazole compounds,
23-33
 we in this work report the 
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synthesis of a novel series of 1,2,3-triazoles tethered to the third position of the 1,2-
benzisoxazole heterocycle, and furthermore examined their cytotoxic effect on cervical 
cancer and acute myeloid leukemia (AML) cells. The synthesis, biological evaluation, as well 
as computational and experimental mode-of-action analysis of those compounds is described 
in the following 
2. Materials and Methods 
2.1. Chemistry 
Melting points were determined on a Selaco melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a Shimadzu FT-IR model 8300 
spectrophotometer. 
1
H NMR spectra were recorded on an NMR spectrometer operating at 
400 MHz using TMS as internal standard. Mass spectra were recorded using electron spray 
ionization mass spectrometry. Elementary analysis was performed using a CE-400 CHN 
analyser. Reactions were monitored by TLC using pre-coated sheets of silica gel G/UV-254 
of 0.25 mm thickness (Merck 60F254) using UV light for visualization. 
All chemicals were obtained from Sigma-Aldrich, Fluka and Merck Chemicals 
2.1.1. General procedure for the synthesis of benzisoxazole-3-azide 3:   
Benzisoxazole-3-amine 2 (2.68 g, 20 mmol) was dissolved in water (25 ml) and 
concentrated HCl (12.5 ml) under vigorous stirring in an ice/water bath. A freshly prepared, 
ice-cold solution of NaNO2 (1.4 g, 20 mmol) in water (10 ml) was added drop wise to the 
reaction mixture by keeping the internal temperature between 0-5 °C. After the completion of 
addition, the reaction mixture was stirred for an additional 10min. A freshly prepared solution 
of sodium azide (1.3 g, 20 mmol) in water (10 ml) was added drop wise to the reaction 
mixture via an additional funnel while keeping the internal temperature of the reaction 
mixture below 5 °C. Upon complete addition of the sodium azide solution, the reaction 
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mixture was stirred for an additional 20-30 min at 0 °C, followed by stirring at room 
temperature for another 3 h. The reaction mixture was extracted with ethyl acetate EtOAc (25 
ml) three times. The combined organic layer was washed with water (25 ml) and brine (25 
ml), dried over anhydrous sodium sulphate and concentrated under reduced pressure to get 
crude benzisoxazole-3-azide 3, which was purified by column chromatography  over silica 
gel (60-120 mesh) using hexane:EtOAc (8:2) as eluent. The pure benzisoxazole-3-azide 3 
was stored at 2-5 °C in the refrigerator. 
2.1.2. General procedure for the synthesis of 1-(3-benzisoxazolyl)-4-aryl-1,2,3-triazoles  
5a-f:  
To the stirred solution of benzisoxazole-3-azide 3  (2 mmol) and alkyne 4 (2 mmol) in 
2 ml of acetonitrile and 1 ml of H2O, copper iodide (0.2 mmol) was mixed at ambient 
temperature. The reaction mixture was stirred at room temperature for 4-8 h (monitored by 
TLC). The reaction mixture was poured into ice cold water (10 ml), extracted with ethyl 
acetate (10 ml) three times. The combined organic layer was washed with water (10 ml), 
followed by brine (10 ml), and dried over anhydrous sodium sulphate, concentrated under 
reduced pressure to get crude 1-(3-benzisoxazolyl)-4-aryl-1,2,3-triazoles 5, which were 
purified by column chromatography over silica gel (60-120 mesh) using hexane:EtOAc (8:2) 
as eluent.  
 2.1.2.1. (4-Phenyl-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5a) 
White solid; m.p. 88-90°C; IR (KBr, cm
-1
) υ 3050, 1701, 1606, 1240, 1110; 1HNMR (400 
MHz, DMSO-d6) δ 9.62 (s, 1H, Ar-H), 8.43 (d, J=8.0 Hz, 1H, Ar-H), 8.14 (d, J=8.0 Hz, 2H, 
Ar-H), 8.00 (d, J=8.0 Hz, 1H, Ar-H), 7.93 (t, J=8.0 Hz, 1H, Ar-H), 7.70 (t, J=7.6 Hz, 1H, Ar-
H), 7.50 (t, J=7.6 Hz, 1H, Ar-H); 
13
C NMR (DMSO-d6, 100 MHz) δ 164.9, 147.1, 145.6, 
130.6, 130.4, 129.2, 128.7, 127.5, 123.1, 123.0, 122.4, 122.2, 121.9: LCMS (MM:ES+APCL) 
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263.3 (M+H)
+
; HPLC 95%. Anal. Calcd for C15H10N4O: C, 68.69; H, 3.84; N, 21.36; Found: 
C, 68.75; H, 3.90; N, 21.41. 
2.1.2.2. (4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5b) 
White solid; m.p. 92-94°C; IR (KBr, cm
-1
) υ 3034, 1706, 1615, 1230, 1125; 1HNMR (400 
MHz, DMSO-d6) δ 9.54 (s, 1H, Ar-H), 8.42 (d, J=8.0 Hz, 1H, Ar-H), 8.02 (t, J=7.4 Hz, 3H, 
Ar-H), 7.92 (t, J=8.2 Hz, 1H, Ar-H),  7.69 (t, J=7.8 Hz, 1H, Ar-H),  7.39 (d, J=8.0 Hz, 2H, 
Ar-H), 2.42 (s, 3H, Ar-Me); 
13
C NMR (DMSO-d6, 100 MHz) δ 164.9, 147.1, 145.0, 131.7, 
130.6, 129.5, 127.4, 125.7, 123.0, 122.4, 122.2, 121.9, 109.6, 21.3; LCMS (MM:ES+APCL) 
277.3 (M+H)
+
; HPLC 95% Anal. Calcd for C16H12N4O: C, 69.55; H, 4.38; N, 20.28; Found: 
C, 69.63; H, 4.46; N, 20.34. 
2.1.2.3. 3-(4-(3-methoxy-5-methylphenyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5c) 
White solid; m.p. 108-110°C; IR (KBr, cm
-1
) υ 3018, 1718, 1602, 1236, 1121; 1HNMR (400 
MHz, DMSO-d6) δ 9.19 (s, 1H, Ar-H), 8.43 (d, J=8.0 Hz, 1H, Ar-H), 8.00 (d, J=8.0 Hz, 1H, 
Ar-H,) 7.93 (t, J=8.0 Hz, 1H, Ar-H), 7.83 (d, J=8.4 Hz, 1H, Ar-H), 7.69 (t, J=7.8 Hz, 1H, Ar-
H), 7.01 (m, 2H, Ar-H), 3.87 (s, 3H, OMe), 2.57 (s, 3H, Ar-Me); 
13
CNMR (DMSO-d63, 100 
MHz) δ 164.9, 161.0, 147.1, 145.0, 139.9, 133.9, 130.6, 123.0, 122.7, 122.4, 122.2, 121.9, 
113.1, 110.6, 109.6, 55.8, 21.9: LCMS (MM:ES+APCL) 307.1(M+H)
+
; HPLC 95%. Anal. 
Calcd for C17H14N4O2: C, 66.66; H, 4.61; N, 18.29; Found: C, 66.72; H, 4.68; N, 18.36. 
2.1.2.4. (4-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5d) 
White solid; m.p. 134-136°C; IR (KBr, cm
-1
) υ 3021, 1698, 1611, 1215, 1136; 1HNMR (400 
MHz, DMSO-d6) δ 9.94 (s, 1H, Ar-H), 8.72 (s, 2H, Ar-H), 8.32 (d, J=6.0 Hz, 1H, Ar-H), 8.14 
(s, 1H, Ar-H), 7.87-7.95 (m, 2H, Ar-H), 7.59-7.65 (m, 1H, Ar-H); 
13
C NMR (DMSO-d6, 100 
MHz) δ 164.9, 147.1, 145.0, 133.6, 131.8 (q), 130.6, 129.8, 124.7, 123.1, 123.0, 122.4, 122.2, 
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121.9, 109.6: LCMS (MM:ES+APCL) 399.86 (M+H)
+
; HPLC 95%. Anal. Calcd for 
C17H8F6N4O: C, 51.27; H, 2.02; N, 14.07; Found: C, 51.32; H, 2.06; N, 14.16. 
2.1.2.5. (4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5e) 
White solid; m.p. 96-98°C; IR (KBr, cm
-1
) υ 3034, 1706, 1615, 1230, 1125; 1HNMR (400 
MHz, DMSO-d6) δ 9.50 (s, 1H, Ar-H), 8.43 (d, J=8.0 Hz, 1H, Ar-H), 8.07 (d, J=9.2 Hz, 2H, 
Ar-H), 8.01 (d, J=8.4 Hz, 1H, Ar-H),  7.93 (t, J=7.8 Hz, 1H, Ar-H),  7.69 (t, J=7.6 Hz, 1H, 
Ar-H), 7.15 (d, J=8.4 Hz, 2H, Ar-H), 3.89 (s, 3H, OMe); 
13
C NMR (DMSO-d6, 100 MHz) δ 
164.2, 159.7, 152.0, 147.5, 132.3, 127.3, 125.6, 123.4, 121.7, 118.9, 114.5, 113.8, 110.7, 
55.2; LCMS (MM:ES+APCL) 293.3 (M+H)
+
; HPLC 95%. Anal. Calcd for C16H12N4O2: C, 
65.75; H, 4.14; N, 19.17; Found: C, 65.81; H, 4.19; N, 19.22. 
2.1.2.6. 3-(4-(4-phenoxyphenyl)-1H-1,2,3-triazol-1-yl)benzo[d]isoxazole (5f) (PTB) 
White solid; m.p. 122-124°C; IR (KBr, cm
-1
) υ 3025, 1699, 1616, 1219, 1139; 1HNMR 
(400MHz, DMSO-d6) δ 9.55 (s, 1H, Ar-H), 8.41 (d, J=8.0 Hz, 1H, Ar-H), 8.14 (d, J=8.8 Hz, 
2H, Ar-H), 7.99 (d, J=7.8 Hz, 1H, Ar-H), 7.90 (t, J=8.0 Hz, 1H, Ar-H), 7.68 (t, J=7.8 Hz, 1H, 
Ar-H), 7.47 (t, J=7.6 Hz, 2H, Ar-H), 7.13-7.24 (m, 5H, Ar-H); 
13
C NMR (DMSO-d6, 100 
MHz) δ 164.9, 157.0, 147.1, 145.0, 130.6, 128.9, 128.4, 127.2, 123.2, 123.0, 122.4, 122.2, 
121.9, 121.8, 118.9, 118.0, 109.6: LCMS (MM:ES+APCL) 355.5 (M+H)+;HPLC 95%. Anal. 
Calcd for C21H14N4O2: C, 71.18; H, 3.98; N, 15.81; Found: C, 71.22; H, 4.03; N, 15.88. 
2.2 Pharmacology 
2.2.1. Cell Culture 
Myeloid leukemia cell lines MOLM13 and MV4-11 were kind gifts by Dr. Martin 
Grundy (Department of Academic Haematology, University of Nottingham). MOLM14 cells 
were generously provided by Dr. Didier Bouscary (Department of Hematology-Immunology, 
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Institut Cochin, Paris, France). Cell lines were cultured and maintained in RPMI medium 
containing 10 % fetal bovine serum (FBS) and 1 % penicillin-streptomycin (Invitrogen, 
Carlsbad, CA) at 37 °C in a humidified atmosphere with 5 % CO2. All cell lines were 
regularly screened for absence of mycoplasma. Bone marrow cells from C57BL/6 mice were 
cultured in IMDM supplemented with 20 % FBS and cytokines (10 ng/ml recombinant 
mouse IL-3, 10 ng/ml recombinant mouse IL-6 and 50 ng/ml recombinant mouse Stem Cell 
Factor (SCF)). 
2.2.2. Cell proliferation assay 
Cellular proliferation of AML cell lines was examined by using methylthiazolyl-
diphenyl-tetrazolium bromide (MTT; Sigma-Aldrich) as described previously.
34
 Briefly, 
8,000 cells per well were seeded in triplicate in 96-well plates (Corning, Lowell, MA, USA) 
in 100 µl of medium containing different concentrations of new compounds. Cells were 
incubated overnight at 37 °C in a CO2 incubator. At the end of the culture duration, 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was added into each well 
until the final concentration of MTT in each well was 0.5 mg/ml. MTT plates were incubated 
at 37 °C in a CO2 incubator for 3 h. After incubation, Formazan crystals were dissolved in 
100 µl of stop solution (SDS-HCl). Absorbance was measured at 570 nm using a Tecan 
Infinite 200 PRO spectrophotometer (Mannedorf, Switzerland). 
2.2.3. Flow cytometric analysis 
To determine the effect of PTB on the cell cycle, cells were treated with PTB at the 
indicated time points as described previously.
35, 36
 Briefly, cells were washed twice with cold 
phosphate-buffered saline (PBS) and fixed with 70 % ethanol (precooled at -20 °C) at 4 °C. 
Cells were incubated with propidium iodide (PI) solution (50 µg/ml PI, 1 % Triton X-100, 20 
µg/ml DNase-free RNase A in PBS for 30 min at 37 °C in the dark. Cell distribution across 
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the cell cycle was analyzed by an LSR-II flow cytometer (Becton- Dickinson, San Jose, CA, 
USA). 
2.2.4 Annexin V and propidium iodide (Annexin V-PI) apoptosis analysis 
Annexin V-PI staining was performed using flow cytometry as described earlier.
34, 37
 
Briefly, 100,000 cells were incubated in 6-well plate with different concentrations of PTB for 
72 h. Staining was carried out using the FITCI Annexin V Apoptosis Detection Kit II (BD 
Biosciences, USA). Cells were washed with ice-cold PBS without Ca
2+
 or Mg
2+
 (Life 
Technologies), resuspended in 100 µl 1X binding buffer and incubated with 5.0 μl of PI and 3 
μl annexin V FITCI for 15 min in dark. The samples were immediately analyzed by LSR-II 
flow cytometer (BD, San Jose, CA, USA). 
2.2.5. Immunoblot analysis 
Western blotting was performed using antibodies against p21, acetylated-tubulin, 
tubulin cyclin D, Beta actin, cleaved PARP and cleaved caspase-9 (Cell Signalling, Boston, 
MA, USA) as described earlier.
38
  
2.2.6. Acid extraction of histones and histones acetylation 
Acid extraction of histones was performed as described previously.
39
 Briefly, MV4-11 
cells were suspended in 5 ml of PBS containing 1X protease inhibitor and centrifuged at 1000 
rpm for 5 min at 4 °C, and the supernatant was discarded. Pellets were resuspended in 5 ml of 
pre-chilled Buffer A (10 mM Tris pH 8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25 % Triton X-
100) for 10 min. After centrifugation, pellets were washed with 5 ml of Buffer B (10 mM 
Tris pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 0.2 M NaCl) and resuspended in 30 mM Tris pH 
7.4, 50 mM EDTA buffer, and sulphuric acid was added to a final concentration of 0.24 M. 
Samples were incubated on ice for 2 h and centrifuged at 13,000 rpm for 15 min. Acetone 
was added into the supernatant, and samples were incubated overnight. The next day, 
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histones were pelleted, air died and resuspended in distilled water containing protease 
inhibitor. The protein concentration was determined using Bradford’s reagent (Bio-Rad 
Protein Assay; Cat. No. 500-0006). The extracted histones were aliquoted and stored at -70 
°C. Histones (0.5 µg) were loaded onto Tris-Glycine 4-20 % gradient gels (Thermo 
Scientific), electrophoresed and transferred to PVDF membranes. The membranes were 
blocked in 5 % milk and incubated with anti-acetyl-Histone H3 antibody (Merck Millipore) 
at 1:1000 dilutions in blocking buffer (5 % milk) overnight at 4 °C on a rocker shaker. 
Membranes were washed with PBS-Tween-20 and incubated with HRP conjugated secondary 
antibody for 1 h. Blots were developed using ECL reagent (Thermo Scientific). Anti-histone 
H3 antibody (Cell signaling) was used as loading control.  
3.  Results and Discussion 
3.1. Synthesis of the scaffold benzisoxazole azide and its triazole derivatives. 
The synthesis of the key intermediate benzisoxazole-3-azide 3 is outlined in Figure 
1A. The benzisoxazole amine 2 was prepared as described previously
40
 by the reaction of 
acetohydroxamic acid with 2-flurobenzonitrile 1 in the presence of potassium tertiary 
butoxide in DMF. Then, the benzisoxazole-3-amine 2 was diazotised followed by in situ 
aromatic nucleophilic substitution by sodium azide to get benzisoxazole-3-azide 3. 
  With the key intermediate benzisoxazole-3-azide 3 in hand, 1-(3-benzisoxazolyl)-4-
aryl-1,2,3-triazoles  5a-f were synthesized through Copper (I)-catalyzed azide-alkyne 
cycloaddition (CuAAC) with various alkynes 4 (Figure 1A). Thus, 1-(3-
benzisoxazolyl)triazoles 5a-f bearing phenyl, 4-methoxyphenyl, 4-methylphenyl,  3,5-
ditrifluromethylphenyl, 3-methoxy-5-methylphenyl and 4-phenoxyphenyl groups at 4-
position were obtained in 82-92 % yield  (Table 1). The structures of all the synthesized 
compounds 5a-f were confirmed by spectral and microanalytical analysis. All final 
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compounds 5a-f showed a characteristic singlet around 9.6 δ corresponding to a proton on the 
triazole ring. 
 
Figure 1. A, Schematic representation of the synthesis of 1-(3-benzisoxazolyl)-4-aryl-1,2,3-
triazoles. Reagents and conditions: (i) Acetohydroxamic acid, t-BuOK, DMF, rt. (ii) 
Conc.HCl, H2O, NaNO2, NaN3, 0˚C. (iii) CuI, acetonitrile:H2O (2:1). B, MTT assays were 
performed after incubation of MV4-11 cells with the indicated concentrations of triazole 
derivatives 5a-f for 72 h. For each concentration, percent inhibition values were calculated 
and data was normalized to diluent controls. Data represent mean ± SD from three 
independent experiments done in quadruplicates. 
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Table 1. Structures of 1-(3-benzisoxazolyl)-4-aryl-1,2,3-triazoles (5a-f) 
Sl. No. Ar (4,5) 5 % Yield 5 
1 C6H5 5a 90 
2 4-MeC6H4 5b 85 
3 3-MeO-5-MeC6H3 5c 92 
4 3,5-(CF3)2C6H3 5d 90 
5 4-MeOC6H4 5e 88 
6 C5H5OC6H4 5f 82 
 
3.2. PTB suppresses cellular proliferation of AML cells in a dose and time dependent 
manner 
Initially we investigated the antiproliferative activity of all compounds against an 
AML cell line (MV4-11) at different concentration (10, 50 and 100 μM) using the MTT 
assay. Among the tested compounds, PTB was found to be most active among the  1,2,3-
triazoles synthesized, exhibiting an IC50 value of 2 µM (see Fig. 1B for all activities 
obtained). PTB was further evaluated on a panel of three AML cell lines including MOLM13, 
MOLM14 and MV4-11 cells. PTB displayed a significant reduction in the number of viable 
cells in all the tested cell lines in a dose- and time-dependent manner (Fig. 2) with the IC50 of 
1 µM, 2 µM and 2.5 µM at 96 hours against MOLM13, MOLM14 and MV4-11 respectively. 
However, PTB did not show a cytotoxic effect on the normal bone marrow cells up to 72 h at 
5 μM and 10 μM concentrations in liquid culture indicating that the PTB does not have 
cytotoxic effect on normal cell (Fig. 3).  
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Figure 2. Cytotoxic effect of PTB against AML cell lines in liquid culture. Panels (A–C): 
PTB displayed a significant reduction in the number of viable cells in  MOLM13, MOLM14 
and MV4-11 cells in a dose- and time-dependent manner. Dotted red line indicates IC50 and 
***, p value <0.0001. 
 
Figure 3. Antiproliferative effect of compound PTB (5, 10 µm PTB against C57BL/6 mouse 
bone marrow cells in liquid culture). MTT assay determined cell viability of C57BL/6 mouse 
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total bone marrow cells. Results represent the mean ± SD of three independent experiments 
with quadruplicate wells per experiment point. NS represents statistically no significant 
difference between control and 5 µM/10 µM PTB. 
3.3. PTB leads to cell cycle arrest in AML cells  
 We next evaluated the effect of PTB on the cell cycle distribution of MOLM13, 
MOLM14 and MV4-11 cells using flow cytometric analysis. MOLM13, MOLM14 and 
MV4-11 cells were treated with PTB up to 72 h and analyzed cell cycle distribution after 
propidium iodide staining. Interestingly, we at longer time interval observed the arrest of cell 
cycle at G2/M phase along with accumulation of AML cells at sub-G1 phase (Fig. 4), while 
the percentage of cells in G1 phase decreased marginally after treatment.  
 
Figure 4. PTB leads to cell cycle arrest in AML cells. A, Fluorescent activated cell sorter 
analyzed the percent MOLM13, MOLM14 and MV4-11 cells in each phase of the cell cycle. 
Arrest of cell cycle at G2/M phase along with accumulation sub-G1 phase was observed PTB 
treatment gradually decreased the percentage of AML cells in G1 phase. The figures are 
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representative of three independent experiments. B, Data are presented in histograms as mean 
± SD of three independent experiments. 
3.4. PTB induces apoptosis of AML cells  
To determine the mechanistic origin of PTB on apoptosis, MOLM13, MOLM14 and 
MV4-11 cells were treated with different concentrations (2.5, 5.0 and 10 μM) of PTB for 72h 
and examined for apoptosis using annexin-V (AV) combined with propidium iodide (PI) 
staining. Flow cytometric analysis clearly showed dose-dependent increase in the percentage 
of apoptotic cells in all the cell lines (Fig. 5A). Next, we examined whether PTB treatment 
induced apoptosis in a caspase-dependent manner. For this, MOLM13 cells were treated with 
varying doses of PTB for 24 h and western blotting was performed for cleaved caspase-9 and 
cleaved PARP (poly ADP ribose polymerase). It was found that PTB induced cleaved PARP 
and caspase-9 in a dose-dependent manner (see Fig. 5B), thereby indicating its mechanism 
via an intrinsic apoptotic pathway. 
 
  
16 
 
Figure 5. Flow cytometry profile upon PTB treatment (Annexin V-FITC staining on the X-
axis vs. PI staining on the Y-axis). The upper left quadrants display the necrotic cells, upper 
right quadrants show the late apoptotic cells, lower left quadrants display the live cells and 
lower right quadrants show the early apoptotic cells. It can be seen that PTB induces 
apoptosis of AML cells in a dose-dependent manner. B, Western blot analysis shows 
increased expression of cleaved caspase-9 and cleaved PARP protein in PTB treated AML 
cells (MOLM13, MOLM14 and MV4-11) compared to control cells. 
Since experimental data suggests DNA damage induced by our compounds, we 
investigated potential direct molecular interactions between DNA and 1,2,3-triazoles. Small 
molecules allow two types of non-covalent interactions with DNA: groove binding and 
intercalation.
41
 DNA minor groove binders usually show characteristic shapes and at least 
two positive charges carried by nitrogen atoms,
42
 which are not at all present in our 
compound series. Therefore, we focused our analyses on potential DNA intercalation and 
performed an in silico docking campaign using the co-crystal structure of DNA and the 
prototypical intercalator actinomycin D (PDB: 173D) as template structure.
43
 After ensuring 
successful redocking of the actinomycin D, we docked all compounds to the intercalation site 
and found clearly less favourable docking scores than for the cognate ligand. Our compound 
series of heterocycles lacks appropriate polycycles for classical intercalation, thus leading to 
fewer Van der Waals contacts and less π-stacking interactions with the DNA base pairs. We 
therefore assume that direct DNA interaction plays only a minor role in the biological 
function of our compounds. 
3.5. In silico mode of action analysis of PTB that targets HDAC6 
In order to understand the mode-of-action of PTB on a molecular level, with respect 
to its abilities of interacting with proteins and modulating pathways involved in apoptosis, we 
subsequently predicted potential protein targets for the series of 1,2,3-triazole derivatives 
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using a  Laplacian-modified Naïve Bayes classifier trained on 155,000 protein-ligand 
annotations extracted from ChEMBL.
44
 We identified potential targets based on class-
specific cut-offs and found different members the family of histone deacetylases (HDACs) 
consistently predicted for all six compounds. This is a target family known to be involved in 
apoptosis modulation,
45
 which we hence decided to follow up first in a structure-based 
manner, in order to gain more support for our hypothesis that PTB targets HDACs on the 
interaction level, and subsequently also to confirm the predictions experimentally. 
3.6. In silico molecular interaction studies of PTB on HDACs. 
Our in silico mode-of-action analysis for the compound PTB revealed that it targets 
HDACs. Previous studies have reported that the diazide-containing isoxazoles were used to 
target histone deacetylases.
46
 Additionally, 3-substituted-1,2-isoxazole was reported to show 
potent inhibitory activity  against HDAC6.
47
 On the other hand, the second deacetylase 
domain of HDAC6 possesses tubulin deacetylase activity,
48
 therefore, we focussed on this 
domain. In absence of an experimental structure, we relied on a homology model from 
SWISS-MODEL
49
 that was based on an HDAC4 structure (PDB: 2VQW, sequence identity = 
47%).
50
 We selected the Zn
2+
 ion as well as its coordinating residues (D649, H651, D742) as 
the centre of the docking sphere and required coordination to the metal ion for all poses taken 
into account further. Docking was performed using MOE's default parameters.
51
 
We observed virtually identical pose predictions for the complete compound series. 
The benzisoxazole and triazole substructures are predicted to coordinate to the active site 
metal ion (Fig. 6). All compounds show a high degree of shape complementarity to the 
binding site of HDAC6, forming multiple molecular interactions in the hydrophobic region as 
well as a hydrogen bond to the phenol side-chain of Tyr-782. Compared to the co-crystal 
structures of HDAC2 inhibitors N-(2-aminophenyl)benzamide (PDB: 3MAX)
52
 and the 
prototypical inhibitor suberanilohydroxamic acid SAHA (PDB: 4LXZ),
53
 similar regions of 
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the binding site are explored including the HDAC foot pocket. The point of variation 
explored in our series is predicted to occupy a solvent-exposed region, thus explaining the 
observed rather flat structure-activity relationship.  
 
Figure 6. Molecular interactions of HDAC inhibitors: A, Molecular interactions between 
HDAC2 and the covalent hydroxamate inhibitor SAHA (PDB: 4LXZ). The protein is shown 
as grey cartoon with the catalytic zinc ion as sphere. Coordinating residues are highlighted as 
thin lines, the bound inhibitor as sticks in elemental colors with carbon in cyan. B, Binding 
pose of N-(2-aminophenyl)benzamide in the HDAC2 binding site (PDB: 3MAX). C, The 
predicted binding mode of PTB in the HDAC6 active site shows a high degree of overlap 
with co-crystal structures of HDAC2 inhibitors. The inhibitor exploits both the foot pocket as 
well as the classic hydrophobic binding site region and forms an additional hydrogen bond to 
Tyr-782 (shown as thin lines in C). Structure-based mode-of-action analysis therefore 
suggests HDACs as the target of PTB to induce apoptosis consistent with ligand. 
3.7. PTB induces acetylation of tubulin and expression of p21 protein 
On the other hand, HDIs have been reported to inhibit deacetylation of non-histone 
proteins such as tubulin.
10, 54
 The major substrate for HDAC6 is tubulin and it functions as 
tubulin deacetylase removing acetylation at lysine 40.
55
 Based on this observation we next 
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evaluated whether PTB treatment enhanced the acetylation of tubulin at lysine 40. Western 
blot analysis showed that treatment of AML cells with PTB resulted in increased acetylation 
of tubulin at lysine 40, thereby  suggesting that PTB may inhibit HDAC6 (Fig. 7A). The 
build-up of acetylated tubulin stabilizes the microtubules and disturb the chromosomal 
alignment during mitosis to induce apoptosis.
13
    
Several studies furthermore reported that HDIs including suberoylanilide hydroxamic 
acid (SAHA), trichostatin A (TSA), FR901228 and oxamflatin induce the expression of p21.
8
 
Therefore, we examined the effect of PTB on the expression of p21 in AML cells. In our 
western blot data, we observed that PTB treatment indeed also induces protein expression of 
p21 (Fig. 7A). Further, reports suggested that HDIs downregulate cyclin D and induce p21 to 
arrest cells in early G1 phase. Therefore, we examined the effect of PTB on cyclin D in 
MOLM13 cells. We observed the decline in the levels of cyclin D in dose-dependent manner 
with maximum inhibition at 10 µM (Fig. 7B). The decrease in cyclin D is unexpected, 
because cyclin D is known to arrest cell cycle at G1 phase which is contradictory to our flow 
cytometry analysis results. However, the previous report suggested that, FR901228 is a 
histone deacetylase inhibitor which downregulates cyclin D1 and arrest cell cycle at G2/M 
phase. The contradictory downregulation of cyclin D1 was explained by the inhibitory effects 
of FR901228 on histone deacetylase.
56
 
3.8. PTB increases histone modification  
Previous studies have demonstrated that the inhibition of HDACs leads to increase in 
acetylation of histone H3 acetylation at lysine 9 (H3K9) and histone H3 acetylation at lysine 
14 (H3K14). Based on the above ligand-based and structure-based in silico mode-of-action 
hypotheses, we next investigated the effect of our lead compound on H3K9. It was found that 
PTB treatment significantly increased the acetylation of H3 in a dose-dependent manner. 
However, PTB had no effect on expression of total histone H3 protein expression (Fig. 7C). 
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The results evidently support our in silico prediction and demonstrates the interference of 
PTB with HDAC activity 
 
 
Figure 7. A, Western blot analysis showing increased expression of p21 and acetylation of 
tubulin in PTB treated AML cells. B, Western blot analysis showing decreased expression of 
Cyclin D in PTB treated AML cells. C, Western blot analysis showing increased acetylation 
of histone H3 in PTB treated AML cells 
4. Conclusions 
The discovery of the HDAC family of proteins, and avenues of how to modulate 
them, has provided a new dimension to the design of therapeutic agents against a broad range 
of cancers via epigenetics approaches. In the present study, a series of novel 1,2,3-triazoles 
have been synthesized and evaluated biologically. PTB was identified as the most potent 
cytotoxic agent against various AML cell lines (MOLM13, MOLM14 and MV4-11 cells), 
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while showing selectivity over bone marrow stem cells. Ligand-based as well as structure-
based analysis of the interaction partners suggested HDACs as a molecular mode-of-action of 
PTB, which has been confirmed in experiment. The lead compound PTB hence significantly 
decreased cell proliferation, induced mitochondrial-mediated apoptosis, and disrupted the cell 
cycle of MOLM13, MOLM14 and MV4-11 cells. Our computational analysis suggested 
HDAC as the target of PTB, which has been validated by increased acetylation of histone H3 
in a dose-dependent manner, as well as induction of p21 and tubulin acetylation. 
Acknowledgements 
The authors are grateful to the Board of Research in Nuclear Sciences (BRNS projects 
vide No. 2009/37/40/BRNS/2266 dated 23‐11‐2009), Institution of Excellence, University of 
Mysore for financial support to KSR. NA thanks the Council for Scientific and Industrial 
Research-University Grants Commission (CSIR-UGC) for senior research fellowship, and 
CDM thanks Department of Science and Technology-Promotion of University Research and 
Scientific Excellence (DST-PURSE) Research Associate fellowship. AB thanks the European 
Research Commission for funding. 
References and Notes 
1. Keerthy, H. K.; Mohan, C. D.; Sivaraman Siveen, K.; Fuchs, J. E.; Rangappa, S.; Sundaram, M. 
S.; Li, F.; Girish, K. S.; Sethi, G.; Basappa; Bender, A.; Rangappa, K. S. The Journal of biological 
chemistry 2014, 289, 31879. 
2. Chen, H. P.; Zhao, Y. T.; Zhao, T. C. Critical reviews in oncogenesis 2015, 20, 35. 
3. Daniel, M.; Tollefsbol, T. O. The Journal of experimental biology 2015, 218, 59. 
4. Ma, J.; Guo, X.; Zhang, S.; Liu, H.; Lu, J.; Dong, Z.; Liu, K.; Ming, L. Molecular medicine reports 
2015, 11, 4525. 
5. Glozak, M. A.; Seto, E. Oncogene 2007, 26, 5420. 
6. Chu, Q. S.; Nielsen, T. O.; Alcindor, T.; Gupta, A.; Endo, M.; Goytain, A.; Xu, H.; Verma, S.; 
Tozer, R.; Knowling, M.; Bramwell, V. B.; Powers, J.; Seymour, L. K.; Eisenhauer, E. A. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO 2015, 26, 973. 
7. Walfridsson, J.; Khorosjutina, O.; Matikainen, P.; Gustafsson, C. M.; Ekwall, K. The EMBO 
journal 2007, 26, 2868. 
8. Blagosklonny, M. V.; Robey, R.; Sackett, D. L.; Du, L.; Traganos, F.; Darzynkiewicz, Z.; Fojo, T.; 
Bates, S. E. Molecular cancer therapeutics 2002, 1, 937. 
9. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. 
International journal of cancer. Journal international du cancer 2007, 121, 1138. 
  
22 
 
10. Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D. Molecular pharmacology 2005, 68, 
917. 
11. Akilov, O. E.; Geskin, L. Skin therapy letter 2011, 16, 1. 
12. Robey, R. W.; Chakraborty, A. R.; Basseville, A.; Luchenko, V.; Bahr, J.; Zhan, Z.; Bates, S. E. 
Molecular pharmaceutics 2011, 8, 2021. 
13. Dowdy, S. C.; Jiang, S.; Zhou, X. C.; Hou, X.; Jin, F.; Podratz, K. C.; Jiang, S. W. Molecular 
cancer therapeutics 2006, 5, 2767. 
14. Odds, F. C.; Brown, A. J.; Gow, N. A. Trends in microbiology 2003, 11, 272. 
15. Kale, P.; Johnson, L. B. Drugs of today (Barcelona, Spain : 1998) 2005, 41, 91. 
16. Geisler, J.; Lonning, P. E. The Journal of steroid biochemistry and molecular biology 2005, 95, 
75. 
17. Howell, A.; Buzdar, A. The Journal of steroid biochemistry and molecular biology 2005, 93, 
237. 
18. Kim, D.-K.; Kim, J.; Park, H.-J. Bioorganic & medicinal chemistry letters 2004, 14, 2401. 
19. Whiting, M.; Tripp, J. C.; Lin, Y.-C.; Lindstrom, W.; Olson, A. J.; Elder, J. H.; Sharpless, K. B.; 
Fokin, V. V. Journal of medicinal chemistry 2006, 49, 7697. 
20. Jain, M.; Kwon, C. H. J Med Chem 2003, 46, 5428. 
21. Sadashiva, M. P.; Basappa, S.; Nanjundaswamy, S.; Li, F.; Manu, K. A.; Sengottuvelan, M.; 
Prasanna, D. S.; Anilkumar, N. C.; Sethi, G.; Sugahara, K.; Rangappa, K. S. BMC chemical biology 2012, 
12, 5. 
22. Newsome, J. J.; Hassani, M.; Swann, E.; Bibby, J. M.; Beall, H. D.; Moody, C. J. Bioorganic & 
medicinal chemistry 2013, 21, 2999. 
23. Chandra, J. N. S.; Malviya, M.; Sadashiva, C.; Subhash, M.; Rangappa, K. S. Neurochemistry 
international 2008, 52, 376. 
24. Novak, M.; Rangappa, K. S.; Manitsas, R. K. The Journal of Organic Chemistry 1993, 58, 7813. 
25. Bharathkumar, H.; Paricharak, S.; Dinesh, K.; Siveen, K. S.; Fuchs, J. E.; Rangappa, S.; Mohan, 
C.; Mohandas, N.; Kumar, A. P.; Sethi, G. RSC Advances 2014, 4, 45143. 
26. Bharathkumar, H.; Mohan, C. D.; Ananda, H.; Fuchs, J. E.; Li, F.; Rangappa, S.; Surender, M.; 
Bulusu, K. C.; Girish, K. S.; Sethi, G. Bioorganic & medicinal chemistry letters 2015. 
27. Sathya, R.; Swamy, J.; Ramesh, S.; Dhananjaya, M.; Nanjundaswamy, A.; Bhadraiah, H.; 
Zameer, F.; Subbaiah, G.; Subbegowda, R. Medicinal chemistry (Shariqah (United Arab Emirates)) 
2014. 
28. Rangaswamy Roopashree, T. R. S., Swamy Jagadish, Chakrabhavi Dhananjaya Mohan, 
Kanchugarakoppal Subbegowda Rangappa. Letters in Drug Design & Discovery 2014, 11, 1143. 
29. Mantelingu, K.; Sadashiva, M.; Rangappa, K. Indian journal of chemistry. Sect. B: Organic 
chemistry, including medical chemistry 2004, 43, 1954. 
30. Rangappa, K. S.; Basappa. Journal of Physical Organic Chemistry 2005, 18, 773. 
31. Sugahara, K.; Thimmaiah, K. N.; Bid, H. K.; Houghton, P. J.; Rangappa, K. S. PloS one 2012, 7, 
e39444. 
32. Fongmoon, D.; Shetty, A. K.; Basappa; Yamada, S.; Sugiura, M.; Kongtawelert, P.; Sugahara, 
K. The Journal of biological chemistry 2007, 282, 36895. 
33. Anusha, S.; Anandakumar, B. S.; Mohan, C. D.; Nagabhushana, G. P.; Priya, B. S.; Rangappa, 
K. S.; Basappa; T, C. G. RSC Advances 2014, 4, 52181. 
34. Keerthy, H. K.; Garg, M.; Mohan, C. D.; Madan, V.; Kanojia, D.; Shobith, R.; Nanjundaswamy, 
S.; Mason, D. J.; Bender, A.; Basappa; Rangappa, K. S.; Koeffler, H. P. PloS one 2014, 9, e107118. 
35. Garg, M.; Okamoto, R.; Nagata, Y.; Kanojia, D.; Venkatesan, S.; M, T. A.; Braunstein, G. D.; 
Said, J. W.; Doan, N. B.; Ho, Q.; Akagi, T.; Gery, S.; Liu, L. Z.; Tan, K. T.; Chng, W. J.; Yang, H.; Ogawa, 
S.; Koeffler, H. P. The Journal of clinical endocrinology and metabolism 2015, 100, 725. 
36. Mohan, C. D.; Bharathkumar, H.; Bulusu, K. C.; Pandey, V.; Rangappa, S.; Fuchs, J. E.; 
Shanmugam, M. K.; Dai, X.; Li, F.; Deivasigamani, A.; Hui, K. M.; Kumar, A. P.; Lobie, P. E.; Bender, A.; 
Basappa; Sethi, G.; Rangappa, K. S. The Journal of biological chemistry 2014, 289, 34296. 
  
23 
 
37. Hayano, T.; Garg, M.; Yin, D.; Sudo, M.; Kawamata, N.; Shi, S.; Chien, W.; Ding, L. W.; Leong, 
G.; Mori, S.; Xie, D.; Tan, P.; Koeffler, H. P. Journal of experimental & clinical cancer research : CR 
2013, 32, 17. 
38. Neelgundmath, M.; Dinesh, K. R.; Mohan, C. D.; Li, F.; Dai, X.; Siveen, K. S.; Paricharak, S.; 
Mason, D. J.; Fuchs, J. E.; Sethi, G.; Bender, A.; Rangappa, K. S.; Kotresh, O.; Basappa. Bioorganic & 
medicinal chemistry letters 2015, 25, 893. 
39. Madan, V.; Madan, B.; Brykczynska, U.; Zilbermann, F.; Hogeveen, K.; Dohner, K.; Dohner, H.; 
Weber, O.; Blum, C.; Rodewald, H. R.; Sassone-Corsi, P.; Peters, A. H.; Fehling, H. J. Blood 2009, 113, 
1444. 
40. Palermo, M. Tetrahedron letters 1996, 37, 2885. 
41. Gurova, K. Future oncology (London, England) 2009, 5, 1685. 
42. Fuchs, J. E.; Spitzer, G. M.; Javed, A.; Biela, A.; Kreutz, C.; Wellenzohn, B.; Liedl, K. R. Journal 
of chemical information and modeling 2011, 51, 2223. 
43. Kamitori, S.; Takusagawa, F. Journal of the American Chemical Society 1994, 116, 4154. 
44. Koutsoukas, A.; Lowe, R.; Kalantarmotamedi, Y.; Mussa, H. Y.; Klaffke, W.; Mitchell, J. B.; 
Glen, R. C.; Bender, A. Journal of chemical information and modeling 2013, 53, 1957. 
45. Facchetti, F.; Previdi, S.; Ballarini, M.; Minucci, S.; Perego, P.; Porta, C. A. M. L. Apoptosis 
2004, 9, 573. 
46. Neelarapu, R.; Holzle, D. L.; Velaparthi, S.; Bai, H.; Brunsteiner, M.; Blond, S. Y.; Petukhov, P. 
A. J Med Chem 2011, 54, 4350. 
47. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. J Med Chem 2008, 
51, 4370. 
48. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Proceedings of 
the National Academy of Sciences of the United States of America 2003, 100, 4389. 
49. Kiefer, F.; Arnold, K.; Kunzli, M.; Bordoli, L.; Schwede, T. Nucleic acids research 2009, 37, 
D387. 
50. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; 
Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi, A. The Journal of biological 
chemistry 2008, 283, 26694. 
51. Molecular Operating Environment (MOE), C. C. G. I.; Montreal, Q., Canada, 2013. 
52. Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; 
Grimshaw, C. E.; Navre, M.; Gangloff, A. R. Bioorganic & medicinal chemistry letters 2010, 20, 3142. 
53. Lauffer, B. E.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; 
Fedorowicz, G.; Vallero, R.; Ortwine, D. F.; Gunzner, J.; Modrusan, Z.; Neumann, L.; Koth, C. M.; 
Lupardus, P. J.; Kaminker, J. S.; Heise, C. E.; Steiner, P. The Journal of biological chemistry 2013, 288, 
26926. 
54. Bhalla, K. N. Journal of Clinical Oncology 2005, 23, 3971. 
55. Aldana-Masangkay, G. I.; Sakamoto, K. M. Journal of Biomedicine and Biotechnology 2011, 
2011, 10. 
56. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M. V.; Bates, 
S. E. British journal of cancer 2000, 83, 817. 
 
  
24 
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Highlights 
 We here describe the coupling of 1,2,3-triazoles to the third position of a 1,2-
benzisoxazole via Copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) with 
various alkynes. 
 PTB has been identified as the lead cytotoxic compound against the AML cell lines. 
 An apoptotic effect of PTB was demonstrated using Annexin-V staining and flow 
cytometry analysis. 
 In silico analysis suggested Histone Deacetylases as the mode-of-action of PTB which 
has been experimentally validated  by showing acetylation patterns in target proteins 
and examining expression of p21. 
